Avidity Biosciences, Inc. — Director's Dealing 2024

May 21, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2024-05-20

Reporting Person: LEVIN ARTHUR A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-20	Common Stock	M	5000	$1.24	Acquired	19830	Direct
2024-05-20	Common Stock	S	5000	$29.8962	Disposed	14830	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-20	Stock Option (Right to Buy)	$1.24	M	5000	Disposed	2030-02-18	Common Stock (5000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	253872	Indirect

Footnotes

F1: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023.

F2: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.23 to $30.36. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof.